Literature DB >> 6282567

Activity ratio measurements reflect intracellular activation of adenosine 3',5'-monophosphate-dependent protein kinase in osteoblasts.

N C Partridge, B E Kemp, S A Livesey, T J Martin.   

Abstract

Parathyroid hormone, prostaglandin E2, and prostacyclin activate cAMP-dependent protein kinase in osteoblast-rich normal rat calvarial cells and in clonal rat osteogenic sarcoma cells of osteoblastic phenotype. The present study was undertaken to determine the activation of the enzyme in relation to cellular cAMP concentrations at increasing doses of the three hormones and also to test that the activity ratio measurement of the enzyme (ratio of the activity in the absence of cAMP to the activity in the presence of excess cAMP) was a true reflection of intracellular activation of the enzyme. With each hormone, using either normal or malignant osteoblasts, activation of the enzyme took place at hormone concentrations lower than those required to produce detectable changes in cAMP concentrations in the incubations. Stimulation of activity was abolished by addition of the heat-stable inhibitor of cAMP-dependent protein kinase, indicating that activation was of cAMP-dependent protein kinase alone. To demonstrate that protein kinase activation occurred intracellularly and not during sample preparation, charcoal was added at the time of cell disruption to absorb free cAMP. Under these conditions, no change was observed in the concentration of bovine parathyroid hormone required to cause activation of cAMP-dependent protein kinase. Finally, addition of purified cAMP-dependent protein kinase type I or type II to treated cells at the time of lysis did not result in significant activation of added isoenzyme, except at hormone concentrations sufficient to increase the total cAMP concentration of incubations. It is concluded that activity ratio measurement reflects the intracellular state of activation of cAMP-dependent protein kinase in the osteoblast-like cells treated by hormones and, furthermore, that only a fraction of the maximally generated cAMP is necessary for full enzyme activation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282567     DOI: 10.1210/endo-111-1-178

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  Historically significant events in the discovery of RANK/RANKL/OPG.

Authors:  T John Martin
Journal:  World J Orthop       Date:  2013-10-18

Review 2.  The pathobiology of the osteoclast.

Authors:  T J Chambers
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

3.  Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin.

Authors:  S M Forrest; K W Ng; D M Findlay; V P Michelangeli; S A Livesey; N C Partridge; J D Zajac; T J Martin
Journal:  Calcif Tissue Int       Date:  1985-01       Impact factor: 4.333

4.  Inhibitory effects of parathyroid hormone on growth of osteogenic sarcoma cells.

Authors:  N C Partridge; A L Opie; R T Opie; T J Martin
Journal:  Calcif Tissue Int       Date:  1985-09       Impact factor: 4.333

5.  Increase in cyclic AMP levels by relaxin in newborn rhesus monkey uterus cell culture.

Authors:  S M Kramer; U E Gibson; B M Fendly; M A Mohler; D W Drolet; P D Johnston
Journal:  In Vitro Cell Dev Biol       Date:  1990-06

6.  Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.

Authors:  Partha Sinha; Piia Aarnisalo; Rhiannon Chubb; Ingrid J Poulton; Jun Guo; Gregory Nachtrab; Takaharu Kimura; Srilatha Swami; Hamid Saeed; Min Chen; Lee S Weinstein; Ernestina Schipani; Natalie A Sims; Henry M Kronenberg; Joy Y Wu
Journal:  J Biol Chem       Date:  2015-11-23       Impact factor: 5.157

7.  Stimulation of creatine kinase BB activity by parathyroid hormone and by prostaglandin E2 in cultured bone cells.

Authors:  D Sömjen; A M Kaye; I Binderman
Journal:  Biochem J       Date:  1985-02-01       Impact factor: 3.857

8.  Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.

Authors:  Tatsuya Tamura; Hiroshi Noda; Eri Joyashiki; Maiko Hoshino; Tomoyuki Watanabe; Masahiko Kinosaki; Yoshikazu Nishimura; Tohru Esaki; Kotaro Ogawa; Taiji Miyake; Shinichi Arai; Masaru Shimizu; Hidetomo Kitamura; Haruhiko Sato; Yoshiki Kawabe
Journal:  Nat Commun       Date:  2016-11-18       Impact factor: 14.919

Review 9.  PTH1R Actions on Bone Using the cAMP/Protein Kinase A Pathway.

Authors:  T John Martin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-19       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.